BridgeMD
New treatment option for Nephrotic Syndrome
Official title Multitarget Strategy for Primary Podocytopathies
ClinicalTrials.gov ID: NCT06718894
What this study is testing
- What it's testing
- The goal of this clinical trial is to verify whether a cell culture system can be used to evaluate the presence of a factor capable of causing proteinuria in the serum of patients with primary podocytopathies. This system will also be used to evaluate the in vitro efficacy of a combined therapy for the treatment of this disorder.
- Time commitment: about 36 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults. Healthy volunteers may be eligible.
You may be able to join if
- Signature of informed consent for study participation
- One of the following conditions:
- Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) showing clinical and/or histological evidence of post-transplant...
- Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) without clinical and/or histological evidence of post-transplant...
- Patients with primary podocytopathies in their native kidneys in an active clinical phase of the disease.
You likely can't join if
- people affected by primary podocytopathies or other glomerulonephritides in clinical remission or with ESRD (eGFR \< 15 ml/min) and/or on renal...
- Individuals unable to understand and consent to the study procedures
- Any clinical condition that, according to the investigator's judgment, could compromise patient safety during study participation
See the full eligibility criteria
- Signature of informed consent for study participation
- One of the following conditions:
- Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) showing clinical and/or histological evidence of post-transplant recurrence.
- Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) without clinical and/or histological evidence of post-transplant recurrence.
- Patients with primary podocytopathies in their native kidneys in an active clinical phase of the disease.
- Patients with podocytopathies presenting clinical features compatible with a secondary form due to another condition.
- Patients with glomerulonephritis other than primary podocytopathies (e.g., IgA nephropathy, systemic lupus erythematosus, membranous nephropathy).
- Patients with no history of renal diseases
- people affected by primary podocytopathies or other glomerulonephritides in clinical remission or with ESRD (eGFR \< 15 ml/min) and/or on renal replacement therapy
- Individuals unable to understand and consent to the study procedures
- Any clinical condition that, according to the investigator's judgment, could compromise patient safety during study participation
The study team makes the final eligibility decision.
Where it's taking place
- Milan, Italy
- Pavia, Italy
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 36 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Milan, Italy; Pavia, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.